Hoppa till innehåll
  • Home
  • About us
    • Team
    • Board of Directors 
  • Our product
    • EMP16
    • Clinical Program
  • Publications
  • News & Media
    • Media
    • Press Releases
    • Blog
  • Contact
  • Home
  • About us
    • Team
    • Board of Directors 
  • Our product
    • EMP16
    • Clinical Program
  • Publications
  • News & Media
    • Media
    • Press Releases
    • Blog
  • Contact

news

  • Home
  • News & Media
Press releases
Empros phase 2b obesity trial enrollment complete in only one month..
Blog
A short overview of the chronic disease obesity
Press releases
Empros pharma doses first patients in large scale clinical study of anti-obesity drug EMP-16
Press releases
Empros secures 80 msek funding to support development of obesity treatment candidate – EMP 16
Press releases
Empros enters late stage clinical development of obesity treatment EMP16 

Empros Pharma was founded in 2013 by researchers and entrepreneurs at Uppsala University together with the investor Flerie Invest. The company is developing EMP16, a pharmaceutical weight management treatment, planned to be ready for launch in 2027. 

Pages

  • Home
  • About us
    • Team
    • Board of Directors 
  • Our product
    • EMP16
    • Clinical Program
  • News & Media
    • Media
    • Press Releases
    • Blog
  • Contact
  • Home
  • About us
    • Team
    • Board of Directors 
  • Our product
    • EMP16
    • Clinical Program
  • News & Media
    • Media
    • Press Releases
    • Blog
  • Contact

Contact

  • info@emprospharma.com
  • Nanna Svartz väg 4, 171 65, Solna
Linkedin
© 2025 empros pharma

Hemsidan är byggd av Weblab